title: Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary.
authors.affiliation: Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands r.hintzen@erasmusmc.nl.
authors.forename: Rogier
authors.initials: R
authors.lastname: Hintzen
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000628:therapy; D010372:Pediatrics
chemical_list: D007155:Immunologic Factors